James C. Katzaroff, CEO& Founder of Advanced Medical Isotope Corporation, called in to SmallCapVoice.com to discuss the recent announcement that ADMD has filed pre-market notification to the FDA pursuant to Section 510(k) of the U.S. Food, Drug and Cosmetic Act for its Yttrium-90 RadioGel(TM) patented brachytherapy cancer product.

Advanced Medical Isotope Corporation (ADMD) is a company engaged in the production and distribution of medical isotopes for advanced diagnostic and non-surgical therapeutic application. AMIC’s goal is to empower physicians, medical researchers, and ultimately patients by providing them with essential medical isotopes that, until recently, have not been feasible or economical, in an effort to detect and cure human disease. For more information, please visit our website, www.isotopeworld.com